

**AMENDMENTS TO THE CLAIMS**

1.-2. (Cancelled)

**3. (Previously presented)** A method of treating diabetes and/or microvascular diabetic complications comprising administering C-peptide or a pharmaceutical composition comprising C-peptide to a patient in a once daily dose, wherein said once daily dose does not include a continuous administration or the presence of release rate-controlling agents.

**4.-9. (Canceled)**

**10. (Previously presented)** The method according to Claim 3, wherein the C-peptide is human C-peptide

**11. (Previously presented)** The method according to Claim 3, wherein said C-peptide is a fragment EGSLQ (SEQ ID NO: 2).

**12. (Previously presented)** The method according to Claim 3, wherein the patient is a human.

**13. (Previously presented)** The method according to Claim 3, wherein the medicament contains 100 to 1800 nmol of C- peptide.

**14. (Previously presented)** The method according to Claim 3, wherein the medicament is an uncompromised aqueous solution.

**15. (Previously presented)** The method according to Claim 3, wherein said complications are diabetic nephropathy, retinopathy or neuropathy.